D
Daniel Sommermeyer
Researcher at Fred Hutchinson Cancer Research Center
Publications - 44
Citations - 5612
Daniel Sommermeyer is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: T cell & T-cell receptor. The author has an hindex of 25, co-authored 41 publications receiving 4368 citations. Previous affiliations of Daniel Sommermeyer include Max Delbrück Center for Molecular Medicine.
Papers
More filters
Journal ArticleDOI
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Cameron J. Turtle,Laïla Aïcha Hanafi,Carolina Berger,Ted Gooley,Sindhu Cherian,Michael Hudecek,Daniel Sommermeyer,Katherine Melville,Barbara S. Pender,Tanya M Budiarto,Emily Robinson,Natalia N Steevens,Colette Chaney,Lorinda Soma,Xueyan Chen,Cecilia Yeung,Brent L. Wood,Daniel Li,Jianhong Cao,Shelly Heimfeld,Michael C. Jensen,Stanley R. Riddell,David G. Maloney +22 more
TL;DR: It is established that high CAR-T cell doses and tumor burden increase the risks of severe cytokine release syndrome and neurotoxicity, and serum biomarkers that allow testing of early intervention strategies in patients at the highest risk of toxicity are identified.
Journal ArticleDOI
Chimeric antigen receptor-modified T cells derived from defined CD8 + and CD4 + subsets confer superior antitumor reactivity in vivo
Daniel Sommermeyer,Michael Hudecek,Michael Hudecek,Paula L. Kosasih,Tea Gogishvili,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle,Stanley R. Riddell,Stanley R. Riddell,Stanley R. Riddell +11 more
TL;DR: It is shown that CAR-T-cell products generated from defined T-cell subsets can provide uniform potency compared with products derived from unselected T cells that vary in phenotypic composition.
Journal ArticleDOI
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Michael Hudecek,Maria Teresa Lupo-Stanghellini,Paula L. Kosasih,Daniel Sommermeyer,Michael C. Jensen,Christoph Rader,Stanley R. Riddell +6 more
TL;DR: T cells modified with an optimized ROR1-CAR have significant antitumor efficacy in a preclinical model in vivo, suggesting they may be useful to treat R OR1+ tumors in clinical applications.
Journal ArticleDOI
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
Michael Hudecek,Michael Hudecek,Daniel Sommermeyer,Paula L. Kosasih,Anne Silva-Benedict,Anne Silva-Benedict,Lingfeng Liu,Christoph Rader,Michael C. Jensen,Michael C. Jensen,Michael C. Jensen,Stanley R. Riddell,Stanley R. Riddell,Stanley R. Riddell +13 more
TL;DR: It is demonstrated that in vivo persistence and antitumor effects of CAR-T cells with a long spacer can be restored by modifying distinct regions in the CH2 domain that are essential for Fc receptor binding.
Journal ArticleDOI
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Alexander I. Salter,Richard G. Ivey,Jacob J. Kennedy,Valentin Voillet,Anusha Rajan,Eva J. Alderman,Uliana J. Voytovich,Chenwei Lin,Daniel Sommermeyer,Lingfeng Liu,Jeffrey R. Whiteaker,Raphael Gottardo,Amanda G. Paulovich,Stanley R. Riddell,Stanley R. Riddell +14 more
TL;DR: The data show that CAR signaling pathways cannot be predicted solely by the domains used to construct the receptor and that signal strength is a key determinant of T cell fate, and suggest that tailoring CAR design based on signal strength may lead to improved clinical efficacy and reduced toxicity.